Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
Work
Year: 2023
Type: article
Abstract: Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo ever... more
Source: Cancer Cell
Institutions Sun Yat-sen University Cancer Center, Sun Yat-sen University, Fujian Provincial Cancer Hospital, Hunan Cancer Hospital, The People's Hospital of Guangxi Zhuang Autonomous Region +21 more
Cites: 24
Cited by: 99
Related to: 10
FWCI: 30.17
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: hybrid
APC paid (est): $9,080